Joshua Hare, MD
Enriched profileLouis Lemberg Professor of Medicine (Cardiology); Senior Associate Dean for Experimental & Cellular Therapeutics; Director, Interdisciplinary Stem Cell Institute and Donald Soffer Endowed Program in Regenerative Medicine, University of Miami Miller School of Medicine · University of Miami Miller School of Medicine
Joshua Hare is Louis Lemberg Professor of Medicine (Cardiology); Senior Associate Dean for Experimental & Cellular Therapeutics; Director, Interdisciplinary Stem Cell Institute and Donald Soffer Endowed Program in Regenerative Medicine, University of Miami Miller School of Medicine at University of Miami Miller School of Medicine. OpenAlex indexes 787 publications with 53,927 citations (h-index 116); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Joshua Hare, MD, FACC, FAHA, is Louis Lemberg Professor of Medicine (Cardiology) at University of Miami Miller School of Medicine. The public record shows 787 publications with 53,927 citations (h-index 116), centered on Mesenchymal stem cell research, Tissue Engineering and Regenerative Medicine, Nitric Oxide and Endothelin Effects. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 8 companies, 15 NIH-funded awards (2006–2024).
- Most recent indexed publication: 2025 · bioRxiv
- Top research focus: Mesenchymal stem cell research
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 366.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
Sponsor: Joshua M Hare
- A Comparative Study of Subjects Past Their Final Follow-ON Visit
Sponsor: University of Miami
Industry payments
Updated 27 Aug 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20253 payments
- Alnylam Pharmaceuticals Inc.Program year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20249 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
76.3%Angiotensin receptor-neprilysin inhibitor (ARNI)22.9%Entresto100%Part D≥18 patientsStatin21.3%Atorvastatin Calcium69%Rosuvastatin Calcium32%Part D<11 patientsBlood & clotting
9.9%P2Y12 inhibitor5.5%Clopidogrel100%Part D<11 patientsFactor Xa inhibitor4.3%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
8.7%SGLT2 inhibitor8.7%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
15 NIH research awards on record, funded 2006–2024 per NIH RePORTER. The latest:
- 1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
Lurie Children'S Hospital of Chicago
FY2024$408,351UH3HL148318 - Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease
University of Miami School of Medicine
FY2024$213,492U01HL169362 - 1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
Lurie Children'S Hospital of Chicago
FY2023$898,221UH3HL148318
Congress activity
Updated 27 Aug 2026
2 congress contributions (2020–2021) across AACR, ENDO per OpenAlex. The most recent:
- Leptin Secreted in the Testicular Microenvironment Promotes the Endogenous Function of Leydig Cells Through Hedgehog Signaling Pathway
ENDO Annual Meeting
ENDO2021Co-author - Abstract 6053: Increased nitric oxide augments the action of CSF-1R inhibition against tumor associated macrophages in castration resistant prostate cancer
AACR (meeting unresolved)
AACR2020Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Growth hormone-releasing hormone signaling and manifestations within the cardiovascular system.
Reviews in endocrine & metabolic disorders
Review2025 - Long term event-free survival following cell-based therapy in patients with cardiomyopathy: the HYPERION observational cohort.
Stem cells translational medicine
Article2025
Most-cited works
by citation count (OpenAlex)- 01Mesenchymal stem cell perspective: cell biology to clinical progressArticle2,037 citations2019
- 02FGF23 induces left ventricular hypertrophyArticle2,005 citations2011
- 03Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyArticle1,724 citations2000
- 04
- 05Myocarditis and inflammatory cardiomyopathy: current evidence and future directionsArticle1,201 citations2020
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/joshua-hare-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
investors.longeveron.com/news/News/news-details/2025/Longeveron-Co-Founder-and-Chief-Science-Officer-Dr--Joshua-Hare-Interviewed-on-NPRs-BioTech-Nation-Discussing-Potential-Breakthrough-Stem-Cell-Therapy-for-Hypoplastic-Left-Heart-Syndrome-HLHS-a-Rare-Pediatric-Congenital-Heart-Defect/default.aspx
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →investors.longeveron.com ↗ - Other
med.miami.edu/podcast/inside-umiami-medicine/2023/harnessing-the-amazing-power-of-stem-cells
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.miami.edu ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu ↗
- MD
FACC, FAHA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu ↗
Editorial & leadership roles
journal and society appointments- Senior Guest Editor
Journal of Cardiovascular Aging
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oaepublish.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.med.miami.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-Founder
Chairman of the Board of Directors, and Chief Science Officer, Longeveron, Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →longeveron.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globenewswire.com ↗
- Guest
The Bioinformatics CRO Podcast
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bioinformaticscro.com ↗ - Video interview
CGTLive: "Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cgtlive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Mario Sznol, MD
University of Miami Miller School of Medicine
Felipe Medeiros, MD
University of Miami Miller School of Medicine
Jeffrey Goldberger, MD
University of Miami Miller School of Medicine
Jonathan Trent, MD
University of Miami Miller School of Medicine